168 related articles for article (PubMed ID: 29454587)
1. Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas.
Lv J; Zhang H; Ma J; Ma Y; Gao G; Song Z; Yang Y
Clin Radiol; 2018 Jun; 73(6):590.e1-590.e8. PubMed ID: 29454587
[TBL] [Abstract][Full Text] [Related]
2. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
3. Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma.
Chen Y; Yang Y; Ma L; Zhu H; Feng T; Jiang S; Wei Y; Wang T; Sun X
Eur J Radiol; 2019 Mar; 112():44-51. PubMed ID: 30777218
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
5. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
Glynn C; Zakowski MF; Ginsberg MS
J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
[TBL] [Abstract][Full Text] [Related]
6. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
[TBL] [Abstract][Full Text] [Related]
7. Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.
Wang H; Schabath MB; Liu Y; Stringfield O; Balagurunathan Y; Heine JJ; Eschrich SA; Ye Z; Gillies RJ
Clin Lung Cancer; 2016 Jul; 17(4):271-8. PubMed ID: 26712103
[TBL] [Abstract][Full Text] [Related]
8. Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective.
AlGharras A; Kovacina B; Tian Z; Alexander JW; Semionov A; van Kempen LC; Sayegh K
Can Assoc Radiol J; 2020 May; 71(2):208-216. PubMed ID: 32062999
[TBL] [Abstract][Full Text] [Related]
9. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
10. CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas.
Han X; Fan J; Gu J; Li Y; Yang M; Liu T; Li N; Zeng W; Shi H
Cancer Imaging; 2020 Jul; 20(1):51. PubMed ID: 32690092
[TBL] [Abstract][Full Text] [Related]
11. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
13. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
14. Computer-Aided Nodule Assessment and Risk Yield (CANARY) may facilitate non-invasive prediction of EGFR mutation status in lung adenocarcinomas.
Clay R; Kipp BR; Jenkins S; Karwoski RA; Maldonado F; Rajagopalan S; Voss JS; Bartholmai BJ; Aubry MC; Peikert T
Sci Rep; 2017 Dec; 7(1):17620. PubMed ID: 29247171
[TBL] [Abstract][Full Text] [Related]
15. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P
Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909
[TBL] [Abstract][Full Text] [Related]
16. Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma--The Results of Three Year Retrospective Analysis.
Bittner N; Balikó Z; Sárosi V; László T; Tóth E; Kásler M; Géczi L
Pathol Oncol Res; 2015 Sep; 21(4):1217-21. PubMed ID: 26055897
[TBL] [Abstract][Full Text] [Related]
17. [Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].
Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Zhou L; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):686-90. PubMed ID: 26582224
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
[TBL] [Abstract][Full Text] [Related]
19. Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.
Rizzo S; Raimondi S; de Jong EEC; van Elmpt W; De Piano F; Petrella F; Bagnardi V; Jochems A; Bellomi M; Dingemans AM; Lambin P
Eur J Radiol; 2019 Jan; 110():148-155. PubMed ID: 30599853
[TBL] [Abstract][Full Text] [Related]
20. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
